Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Heterozygous familial hypercholesterolemia (heFH) - Drugs In Development, 2022, provides an overview of the Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) pipeline landscape.
Heterozygous familial hypercholesterolemia (HeFH) is a genetic disorder caused due to a mutation (alteration) of FH from one (affected) parent. Symptoms include xanthesmas, corneal arcus, aortic rupture and peripheral vascular disease. Risk factors include age, sex, smoking and hypertension, or associated lipid abnormalities such as low HDL-C levels, high TG levels, or presence of type III dyslipoproteinemia.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Heterozygous familial hypercholesterolemia (heFH) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Heterozygous familial hypercholesterolemia (heFH) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Discovery and Unknown stages are 2, 5, 5, 1, 1 and 1 respectively.
Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Heterozygous familial hypercholesterolemia (heFH) - Overview
Heterozygous familial hypercholesterolemia (heFH) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Heterozygous familial hypercholesterolemia (heFH) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Heterozygous familial hypercholesterolemia (heFH) - Companies Involved in Therapeutics Development
Akeso Inc
Amgen Inc
Beijing Mabworks Biotech Co Ltd
Daewoong Pharmaceutical Co Ltd
Epicrispr Biotechnologies Inc
Esperion Therapeutics Inc
Innovent Biologics Inc
LIB Therapeutics LLC
NeuroBo Pharmaceuticals Inc
NewAmsterdam Pharma BV
Novartis AG
Regeneron Pharmaceuticals Inc
Shanghai Junshi Bioscience Co Ltd
Verve Therapeutics Inc
Heterozygous familial hypercholesterolemia (heFH) - Drug Profiles
alirocumab - Drug Profile
Product Description
Mechanism Of Action
bempedoic acid - Drug Profile
Product Description
Mechanism Of Action
ebronucimab - Drug Profile
Product Description
Mechanism Of Action
EPIC-221 - Drug Profile
Product Description
Mechanism Of Action
evinacumab - Drug Profile
Product Description
Mechanism Of Action
evolocumab - Drug Profile
Product Description
Mechanism Of Action
gemcabene - Drug Profile
Product Description
Mechanism Of Action
inclisiran - Drug Profile
Product Description
Mechanism Of Action
lerodalcibep - Drug Profile
Product Description
Mechanism Of Action
MIL-86 - Drug Profile
Product Description
Mechanism Of Action
obicetrapib - Drug Profile
Product Description
Mechanism Of Action
ongericimab - Drug Profile
Product Description
Mechanism Of Action
ST-103 - Drug Profile
Product Description
Mechanism Of Action
tafolecimab - Drug Profile
Product Description
Mechanism Of Action
VERVE-101 - Drug Profile
Product Description
Mechanism Of Action
Heterozygous familial hypercholesterolemia (heFH) - Dormant Projects
Heterozygous familial hypercholesterolemia (heFH) - Discontinued Products
Heterozygous familial hypercholesterolemia (heFH) - Product Development Milestones
Featured News & Press Releases
Sep 21, 2022: Verve Therapeutics announces clearance of clinical trial authorisation application by the United Kingdom Medicines and Healthcare Products Regulatory Agency for VERVE-101 in patients with heterozygous familial hypercholesterolemia
Aug 29, 2022: New Amgen data at ESC 2022 show long-term LDL-C lowering with REPATHA (evolocumab) was well-tolerated for more than 8 years
Aug 29, 2022: NewAmsterdam Pharma showcases leadership in cardiometabolic disease treatment in multiple presentations at ESC congress 2022
Aug 29, 2022: AMGEN to present new data at ESC Congress 2022 highlighting up To 8.5 years of Repatha (Evolocumab) safety and tolerability data in high-risk ASCVD patient populations
Jul 28, 2022: NewAmsterdam pharma doses first patient in phase 3 BROOKLYN clinical trial evaluating obicetrapib in patients with heterozygous familial hypercholesterolemia
Jul 12, 2022: Verve Therapeutics doses first human with an investigational in vivo base editing medicine, VERVE-101, as a potential treatment for heterozygous familial hypercholesterolemia
May 09, 2022: Verve Therapeutics reports additional VERVE-101 and GalNAc-Lipid Nanoparticle Delivery data in non-human primates at TIDES USA 2022
May 02, 2022: Esperion announces publication of CLEAR Harmony open-label extension study data for Bempedoic Acid in the American Journal of Cardiology
Apr 27, 2022: Amgen announces results from two open label extension studies of Repatha (evolocumab)
Apr 03, 2022: Innovent releases results of a phase 3 clinical study of IBI306 (PCSK-9 inhibitor) in Chinese patients with heterozygous familial hypercholesterolemia at the American College of Cardiology Annual Congress 2022
Feb 08, 2022: Leqvio therapy to lower cholesterol approved by FDA, IVX Health now accepting new Leqvio patients
Oct 15, 2021: Amgen’s evolocumab receives positive CHMP opinion for the treatment of Heterozygous familial hypercholesterolemia and Familial Hypercholesterolemia
Sep 24, 2021: FDA approves Repatha (evolocumab) in pediatric patients age 10 and older with heterozygous familial hypercholesterolemia
Aug 12, 2021: Innovent’s antibody therapy meets primary goal in Phase III HeFH trial
May 19, 2021: Verve Therapeutics announces Nature publication highlighting its use of base editing to potently and durably lower blood PCSK9 and LDL-C in non-human primates
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Heterozygous familial hypercholesterolemia (heFH), 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Akeso Inc, 2022
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Amgen Inc, 2022
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Beijing Mabworks Biotech Co Ltd, 2022
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Daewoong Pharmaceutical Co Ltd, 2022
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Epicrispr Biotechnologies Inc, 2022
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Esperion Therapeutics Inc, 2022
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Innovent Biologics Inc, 2022
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by LIB Therapeutics LLC, 2022
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by NeuroBo Pharmaceuticals Inc, 2022
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by NewAmsterdam Pharma BV, 2022
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Novartis AG, 2022
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Regeneron Pharmaceuticals Inc, 2022
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Verve Therapeutics Inc, 2022
Heterozygous familial hypercholesterolemia (heFH) - Dormant Projects, 2022
Heterozygous familial hypercholesterolemia (heFH) - Discontinued Products, 2022
List of Figures
Number of Products under Development for Heterozygous familial hypercholesterolemia (heFH), 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
